(Q46514310)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Cost of lipid lowering in patients with coronary artery disease by case method learning (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

main subject

coronary artery disease

1 reference

Anna Kiessling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Niklas Zethraeus

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Peter Henriksson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Technology Assessment in Health Care

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

180-186

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Accounting for future costs in medical cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

The weighting exercise for the Swedish version of the EuroQol

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Modeling valuations for EuroQol health states

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Why don't physicians follow clinical practice guidelines? A framework for improvement

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Willingness to pay for a quality-adjusted life year: in search of a standard

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

The cost-effectiveness of a cardiovascular risk reduction program in general practice.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

Efficacy of case method learning in general practice for secondary prevention in patients with coronary artery disease: randomised controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

EuroQol: the current state of play

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://api.crossref.org/works/10.1017%2FS0266462305050245

7 January 2021

10.1017/S0266462305050245

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921057%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference